Ghanizadeh 2008b.

Methods	A patient report of nocturnal enuresis during methylphenidate treatment
Participants	Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: 11 years old IQ > 80 Sex: male Ethnicity: Persian Country: Iran Comorbidity: no Comedication: not stated Sociodemographics: not stated
Interventions	Methylphenidate dose: 20 mg/day, 2 months. Discontinuation of methylphenidate for 1,5 months. Re‐administering of methylphenidate, 20 mg/day, 3 months Discontinuation of methylphenidate, some months. Re‐administering of methylphenidate, 20 mg/day, 2 months. Discontinuation of methylphenidate Type of methylphenidate: not known Administration schedule: not stated Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Methylphenidate titrated to 20 mg/day: nocturnal enuresis Discontinuation of methylphenidate: enuresis stopped immediately Methylphenidate, when titrated to 20 mg/day: immediate re‐occurence of nocturnal enuresis Discontinuation of MPH: enuresis stopped immediately Methylphenidate, when titrated to 20 mg/day: immediate re‐occurence of nocturnal enuresis Discontinuation of MPH: enuresis stopped immediately
Notes	Ethics approval: not stated Funding/vested interests: not stated Key conclusions of study authors: clinicians should be aware of this potential side effect of methylphenidate Comments from the study author: although both the boy and his mother were interviewed to obtain precise information, it should be noted that the boy may be suffering from a non‐standard type of enuresis or the parents may be biased to see a connection between drug and enuresis that does not exist. Future researches are necessary to study if there is any possible association Supplemental information was received through personal email correspondence with the author in July 2013 (Ghanizadeh 2013 [pers comm])